Orexo strives to ensure that analysts, investors and financial media are provided with correct and timely information. We will also build and maintain relationships based on credibility. In this way we contribute to an accurate valuation of the Company. Orexo’s share is listed on Nasdaq Stockholm and available as American Depository Receipts (ADRs) on OTCQX in the US.
JANUARY 30, 2020 – In 2019 we delivered the strongest financial results, with Q4 being no exception. The development was driven YoY increased net revenues for Zubsolv and strong cost control. Operationally, we signed two partnership agreements with GAIA to develop digital therapeutics for the treatment of Opioid and Alcohol Use Disorder and we made pipeline progresses. With a solid cash position we will continue to deliver our strategy for future growth with the aim to build an even more exciting future.
